{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-029914","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.361240+00:00","generated_at":"2026-05-23T19:17:28.530324+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ImmuCell reports record Q1 2025 sales of $8.1M, up 11% YoY","bullets":["Preliminary unaudited product sales for Q1 2025: $8.1M, up 11% from $7.3M in Q1 2024.","All-time quarterly sales record; six-month ($15.8M) and twelve-month ($27.3M) periods also record.","Order backlog reduced to $4.0M as of March 31, 2025, from $4.4M at Dec 31, 2024.","Annualized Q1 sales were approximately 108% of estimated $30M annual capacity.","NADA submission for Re-Tain progressing; critical path remains inspection at contract manufacturer."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-029914","json":"https://secwatch.observer/filing/0001213900-25-029914.json","markdown":"https://secwatch.observer/filing/0001213900-25-029914.md","text":"https://secwatch.observer/filing/0001213900-25-029914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390025029914/0001213900-25-029914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390025029914/ea0237552-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:17:28.530324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}